Search Result

Isoforms Recommended:	IKZF1

Results for "

IKZF1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (12) Btk (1) c-Myc (1) Casein Kinase (4) CDK (3) E1/E2/E3 Enzyme (1) FLT3 (1) Fluorescent Dye (1) Histone Methyltransferase (1) IKZF Family (14) Interleukin Related (1) Isotope-Labeled Compounds (3) Ligands for E3 Ligase (10) MAP4K (1) Molecular Glues (21) Phosphodiesterase (PDE) (2) PROTACs (10) Reference Standards (1) Small Interfering RNA (siRNA) (3) WDR5 (1)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (12)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS06665

IKZF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IKZF1 Human Pre-designed siRNA Set A contains three designed siRNAs for IKZF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IKZF1 Human Pre-designed siRNA Set A IKZF1 Human Pre-designed siRNA Set A

HY-144841

Cemsidomide CFT7455	Molecular Glues IKZF Family	Cancer
Cemsidomide (CFT7455) is a ubiquitin ligase pathway based *IKZF1/3* (Ikaros/Aiolos) degrader with molecular glue activity ^[1]. Cemsidomide has a GI₅₀ of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM) ^[1] .

HY-111594

Homo-PROTAC cereblon degrader 1 1 Publications Verification	PROTACs	Cancer
Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient Cereblon (CRBN) degrader with only minimal effects on *IKZF1* and *IKZF3* ^[1].

HY-162014

WDR5 degrader-1	PROTACs WDR5	Cancer
WDR5 degrader-1 (compound 25) is a cereblon (CRBN)-recruiting WDR5 degrader. WDR5 degrader-1 selectively degraded WDR5 over the CRBN neo-substrate IKZF1 ^[1].

HY-RS23139

Ikzf1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ikzf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ikzf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ikzf1 Rat Pre-designed siRNA Set A Ikzf1 Rat Pre-designed siRNA Set A

HY-RS16704

Ikzf1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ikzf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ikzf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ikzf1 Mouse Pre-designed siRNA Set A Ikzf1 Mouse Pre-designed siRNA Set A

HY-160531

IKZF1-degrader-1	Molecular Glues IKZF Family	Cancer
IKZF1-degrader-1 (Compound 9-B) is a *IKZF1* molecular glue degrader with the DC₅₀ value of 0.134 nM. IKZF1-degrader-1 can be used to degrader tumors ^[1].

HY-160533

IKZF1-degrader-2	Molecular Glues IKZF Family	Cancer
IKZF1-degrader-2 (Compound 3) is an *IKZF1* molecular glues degrader. IKZF1-degrader-2 has anticancer activity and low toxicity ^[1].

HY-175600

MI-2-80	IKZF Family Casein Kinase Molecular Glues	Cancer
MI-2-80 is a molecular glue degrader. MI-2-80 induces proteins (such as *IKZF1/3* and *CSNK1A1*) to bind to CRBN, promoting their ubiquitination and degradation ^[1].

HY-175601

DD-04-038	IKZF Family Molecular Glues	Others
DD-04-038 is a molecular glue degrader. DD-04-038 induces proteins (such as *IKZF1/3, ZBED3* and *PATZ1*) to bind to CRBN, promoting their ubiquitination and degradation ^[1].

HY-175602

TM-04-064-02	IKZF Family Phosphodiesterase (PDE) Molecular Glues	Others
TM-04-064-02 is a molecular glue degrader. TM-04-064-02 induces proteins (such as *IKZF1/3, PPIL4, ETF1* and PDE6D) to bind to CRBN, promoting their ubiquitination and degradation ^[1].

HY-A0003B

Lenalidomide hemihydrate Maximum Cited Publications 51 Publications Verification CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003

Lenalidomide Maximum Cited Publications 51 Publications Verification CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Inflammation/Immunology Cancer
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-175040

PROTAC FLT-3 degrader 5	PROTACs Molecular Glues FLT3 IKZF Family	Cancer
PROTAC FLT-3 degrader 5 is a FLT3 PROTAC degrader (DC₅₀ = 1.2 nM). PROTAC FLT-3 degrader 5 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT-3 degrader 5 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide: (HY-14658); Black: linker; Thalidomide + linker: (HY-W1123823)) ^[1].

HY-143435

AG6033	Apoptosis	Cancer
AG6033 is a potential novel CRBN modulator. AG6033 suppresses various tumor cells by modulating the interactions between CRBN and various antitumor target proteins. AG6033 can cause GSPT1 and IKZF1 degradation. AG6033 induces CRBN-dependent cytotoxic effect ^[1].

HY-145776

ALV1	Molecular Glues Ligands for E3 Ligase IKZF Family Interleukin Related	Inflammation/Immunology Cancer
ALV1 is a molecular glue degrader for Ikaros (IKZF1) and Helios (IKZF2) with DC₅₀ of 2.5 nM and 10.3 nM respectively. ALV1 bind CRBN with an IC₅₀ of 0.55 μM, and induces CRBN-Helios dimerization. ALV1 can be used to study the properties and functions of regulatory T cells ^[1].

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Inflammation/Immunology Cancer
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease ^[1] .

HY-A0003BR

Lenalidomide hemihydrate (Standard)	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide (hemihydrate) (Standard) is the analytical standard of Lenalidomide (hemihydrate). This product is intended for research and analytical applications. Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003R

Lenalidomide (Standard) CC-5013 (Standard)	Reference Standards Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-168614

MGD-4	IKZF Family	Cancer
MGD-4 is an orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades *IKZF1* (DC₅₀=67.2 nM), *IKZF2* (DC₅₀=918.2 nM), and *IKZF3* (DC₅₀=95.8 nM) in a dose-dependent manner. MGD-4 effectively inhibits the growth of multiple myeloma ^[1].

HY-A0003S2

Lenalidomide-13C5,15N CC-5013-¹³C₅,¹⁵N	Ligands for E3 Ligase Apoptosis Molecular Glues Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-123714

TL4-12	MAP4K Apoptosis	Inflammation/Immunology Cancer
TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC₅₀=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM) ^[1].

HY-W760183

EM12-SO2F	Fluorescent Dye	Cancer
EM12-SO2F is a powerful covalent inhibitor of CRBN through binding at His353. EM12-SO2F is a useful chemical probe to investigate the CRBN. EM12-SO2F inhibits the degradation of *IKZF1* by lenalidomide (HY-A0003) in MOLT4 cells ^[1]

HY-136262

CRBN-6-5-5-VHL	PROTACs E1/E2/E3 Enzyme	Cancer
CRBN-6-5-5-VHL is a potent and selective von Hippel-Lindau-based cereblon (CRBN) degrader with a DC₅₀ value of 1.5 nM. CRBN-6-5-5-VHL has almost no effect on the degradation of the neo-substrates IKZF1 and IKZF3. (Pink: VHL ligand (HY-125845); Blue: E3 Ligase ligand (HY-10984); Black: linker (HY-403544)) ^[1].

HY-168615

MGD-28	IKZF Family Casein Kinase	Cancer
MGD-28 is a potent, orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades *IKZF1* (DC₅₀=3.8 nM), *IKZF2* (DC₅₀=56.3 nM), and *IKZF3* (DC₅₀=7.1 nM) in a dose-dependent manner. In addition, MGD-4 also degrades *CK1α* (DC₅₀=7.8 nM). MGD-28 has antiproliferative activity and can be used in multiple myeloma research ^[1].

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity ^[1].

HY-136250A

BSJ-03-204 triTFA	PROTACs CDK	Cancer
BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity ^[1].

HY-136252

BSJ-04-132	PROTACs CDK	Cancer
BSJ-04-132 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC₅₀s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity ^[1].

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003S3

Lenalidomide-d4 CC-5013-d₄	Isotope-Labeled Compounds Apoptosis Molecular Glues Ligands for E3 Ligase	Inflammation/Immunology Cancer
Lenalidomide-d₄ (CC-5013-d₄) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-148837

GT19630	PROTACs c-Myc Casein Kinase	Infection Cardiovascular Disease Cancer
PROTAC c-Myc degrader-1 (Compound A153) is a multiple target protein degrader (PROTAC). PROTAC c-Myc degrader-1 effective degrades c-MYC, *CK1α, GSPT1* and *IKZF1/2/3* proteins in a variety of tumor cells. PROTAC c-Myc degrader-1 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection (Pink: c-Myc ligand (HY-168685); Blue: E3 ligase ligand (HY-W093472); Black: linker (HY-W015808)) ^[1].

HY-175502

MGD-22	Molecular Glues IKZF Family Apoptosis	Cancer
MGD-22, a molecular glue, is an orally active *IKZF1/2/3* degrader with DC₅₀ values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL) ^[1].

HY-W1128213

IKZF2-degrader 2	Molecular Glues IKZF Family	Inflammation/Immunology Cancer
IKZF2-degrader 2 is a selective and orally active *IKZF2* molecular glue degrader with DC₅₀ values of 0.5 nM and 1.8 nM in HiBit and FACS. The IKZF2-degrader 2 mediates the ubiquitination and degradation of target proteins by recruiting the CRL4-CRBN E3 ubiquitin ligase. IKZF2-degrader 2 displays moderate degradation against SALL4 with a DC₅₀ of 9 nM but does not induce any significant degradation towards IKZF1, IKZF3, CK1α and GSPT1. IKZF2-degrader 2 can be used for the study of cancer immunology ^[1].

HY-153220

NX-2127	PROTACs Btk	Cancer
NX-2127 (Compound 28) is an orally active PROTAC deggrader, targeting to Bruton’s Tyrosine Kinase (Btk) . NX-2127 inhibits proliferation of BTK ^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells ^[1] . (Pink: BTK ligand 10 (HY-168302); Black: (R)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168348); Blue: Thalidomide 5-fluoride (HY-W087383)

HY-170518

IKZF-IN-1	IKZF Family Molecular Glues	Infection Cancer
IKZF-IN-1 (Compound I) is the molecular glue, that degrades ikaros zinc finger family (IKZF) IKZF 1/2/3/4, and can be used as an immunomodulator in research of cancer and viral infections ^[1].

HY-130800

Eragidomide 4 Publications Verification CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation ^[1] .

HY-172368

*PROTAC CARM1/IKZF3 degrader-1*	PROTACs Histone Methyltransferase IKZF Family Apoptosis	Inflammation/Immunology Cancer
PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits *CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3* degrader-1 is the PROTAC degrader for *IKZF 1/3* through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research ^[1]. (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369); Active form of target protein ligand: EZM 2302 (HY-111109); Black: linker (HY-21999); Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547))

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003S2

Lenalidomide-13C5,15N
Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Lenalidomide-13C5,15N

Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

HY-A0003S3

Lenalidomide-d4
Lenalidomide-d₄ (CC-5013-d₄) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Lenalidomide-d4

Lenalidomide-d₄ (CC-5013-d₄) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells ^[1] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81282

	Ikaros Antibody (YA987) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; IKZF1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	WB, IP	Human
	Ikaros Antibody (YA987) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Ikaros.

HY-P85438

	Ikaros Antibody (YA5130) IKZF1; IK1; IKAROS; LYF1; ZNFN1A1; DNA-binding protein Ikaros; Ikaros family zinc finger protein 1; Lymphoid transcription factor LyF-1	WB	Human, Mouse, Dog
	Ikaros Antibody (YA5130) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Ikaros.

HY-P81282A

	Ikaros Antibody (YA988) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; IKZF1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.	IHC-P	Human
	Ikaros Antibody (YA988) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ikaros.

HY-P85524

	Ikaros(C-term) Antibody (YA5216) CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros; zinc finger protein; IKAROS; IKAROS family zinc finger 1; Ikaros; Ikaros family zinc finger protein 1; IKZF1; IKZF1_HUMAN; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1; Ikaros; zinc finger protein subfamily 1A 1; Zinc finger protein, subfamily 1A, member 1; ZNFN1A1.	WB, IP	Human
	Ikaros(C-term) Antibody (YA5216) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Ikaros(C-term).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: